Advancing in the battle against cancer

Proliferative and invasive capacity of tumour cells (centre) compared to normal cells (left) and effect of TRAMETINIB treatment, which reduces the invasive capacity and tumoural load (right). Marco Milán, IRB Barcelona.

Proliferative and invasive capacity of tumour cells (centre) compared to normal cells (left) and effect of TRAMETINIB treatment, which reduces the invasive capacity and tumoural load (right). Marco Milán, IRB Barcelona.


The programme El Matí, broadcasted on Catalunya Ràdio, and the newspapers La Vanguardia and El Punt Avui, among other media, have echoed on a study led by Marco Milán, head of the Development and Growth Control Laboratory at IRB Barcelona. This study reports on the team’s success in selectively eliminating cells that express the oncogene RAS. This oncogene is activated in 30% of humans cancers, and no effective inhibitors of this protein had been identified to date.

Link to Catalunya Ràdio  

Link to La Vanguardia

Link to El Punt Avui